Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-184-7 | CAS number: 79-19-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
Key study: Under the test conditions, thiosemicarbazide gave somewhat ambiguous results, through administered at high enough dose levels to be toxic.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- significant methodological deficiencies
- Remarks:
- No GLP study.
- Qualifier:
- according to guideline
- Guideline:
- other: Guideline for carcinogen bioassay in small rodents (Washington, D.C.:US Govt Print Off, 1976)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Carcinogenicity testing: A report of the panel of the Cancer Research Commission of UICC, Vol 2. Geneva: UICC, 1969
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- 1.In the study, 26 animals/each sex were used,but according the TG 451 there should be used 50 animals/each sex. 2.The length of test. In the present study,length of the test was 18 months, but according the TG 451 the length should be 24 months.
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- other: Charles River CD
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:Breeding laboratories, Non Wilmington, Mass.
- Housing: 2 per large plastic cage (12x14x7 inches) on corncob bedding (San-i-cel; Paxton Processing Co.,Inc., Paxton, Ill.).
- Diet (e.g. ad libitum):Wayne Lab Blox meal. Mixtures prepared as for the animal diets were stored for 10 days at room temperature to determine the possible degradation of the compound added.
- Water (e.g. ad libitum): ad libitum.
- Acclimation period:7-10 days
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
For diet mixing, a small portion of meal was mixed thoroughly in a mortar with the proper amount of the compound; the resultant concentrate was added to more meal and blended for 15-20 minutes in a twin-shell blender.
DIET PREPARATION
- Rate of preparation of diet (frequency):Diet was prepared in 6-kg lots twice weekly
- Storage temperature of food:in refrigerator at 4ºC
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Required level (ppm): 100-200
Recovery (%) : 83.8+-3.8
Stability in days: 10
Loss % : none - Duration of treatment / exposure:
- Total weeks on drug: 78
- Frequency of treatment:
- Daily
- Post exposure period:
- 6 months
- Dose / conc.:
- 75 ppm
- Remarks:
- The high dose
- Dose / conc.:
- 37.5 ppm
- Remarks:
- The low dose
- No. of animals per sex per dose:
- 26 animals per dose/sex (total 104)
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: The doses were selected according the previous study on Acute toxicity. Five distinct levels of each compund were mixed in diet, or given twice weekly in stomach tube to groups of 3 animals each over 30 days, followed by 30 days fo observation for detection of delayed toxicity.
- Positive control:
- 2 groups with N-2-fluorenylacetamide in the diet at 80 ppm (32 rats) or 250 ppm (20 rats).
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes (mortality)
DETAILED CLINICAL OBSERVATIONS: Yes (The presence of palpable masses was noted during weighting, transfer to clean cages.)
- Time schedule: Twice daily, 7 days a week for toxicologic effects and death
BODY WEIGHT: Yes
- Time schedule for examinations: weekly during the initial month of the chronic study and beewekly thereafter.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined: Yes - during the initial week and the fourth week of each subsequent 4-week period.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: No data
CLINICAL CHEMISTRY: No data
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: No data
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes, The tissues were fixed in 10% neutral buffered Formalin, sectioned, and stained with hematoxylin and eosin.Examintaion:cerebrum, cerebellum,pituitary gland, spinal cord plus vertebrae, lung, heart,mediastinum, thymus, thyroid gland, parathyroid gland,liver, spleen, pancreas, adrenal gland, kidney, urinary bladder, ovary, uterus or testis, accessory sex organ, esophagus, stomach, intestinal tract, and any abnormal tissue or mass.Animals were necropsied, and stained sections of the tissues were examined microscopically to detect any changes. - Statistics:
- Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (10), which is commonly called the "life table method." Animals were statistically censored as of the time they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. For statistical analyses of a possible dose-related effect on survival, the method : extensions of Cox's methoas for testing for a dose-related trend were used.
One-tailed Fisher's exact probability test was used to compare the tumor incidence of a matched negative or vehicle control group with that of a group of dosed animals at each dose level. Inasmuch as the results for 2 dosed groups were compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 could be made.
The Bonferroni inequality requires that the P-value for any comparison be less than or equal to 0.0512 = 0.025.
The Cochran-Armitage test for linear trend in proportions, with continuity correction was also used, if the slope of the dose-response curve is different from zero at the one-tailed 0.05 level of significance. - Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Low dose females had greater mortality than matched negatve controls had.
At least 22 animals of each treated group survived to 78 weeks.
In the matched control group, male survivals were only 9 and females survivals was 10. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weight from the treated groups (high dose) was less than in the matched or pooled groups, but no difference noted with treated gropus (low dose).
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose group: 2 females had mammary adenocarcinomas.
Low dose group, pooled or matched group: None. The diference was not significant.
Ten negative control groups, females: 4 mammary carcinonoms of 184 animals
In the 184 control animals, the incidence of mammary tumors was 45%, which is less than the rate in either the low or high-dose groups but considerably above the 30 and 35% found in the matched and pooled negative controls respectively.
One negative control group had an incidence exceeding the 73% in the low-dose group, and 2 other groups had incidences approaching the 62% in the high-dose groups. - Other effects:
- not examined
- Relevance of carcinogenic effects / potential:
- The author of this study confirmed that these results are ambiguous.
- Key result
- Dose descriptor:
- conc. level:
- Effect level:
- ca. 75 ppm
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
- Remarks on result:
- other: Ambiguous results
- Key result
- Critical effects observed:
- not specified
- Conclusions:
- Under the test conditions, thiosemicarbazide gave somewhat ambiguous results, though administered at high enough dose levels to be toxic.
- Executive summary:
According the publication from the Journal of the National Cancer Institute,the test item was tested for the carcinogenicity in the Charles River rats. In this chronic study chemicals was given to groups of 26 male and 26 female in the maximum tolerated doses and its half amount (75 ppm and 37.5 ppm) in a diet form during 78 weeks. After the treatment, they were observed during 6 months.Control groups animal (matched and pooled) were used in the study.Two positive control groups with the N-2 -fluorenylacetamide were used to check the response to a known carcinogen at different dose level (80 ppm and 250 ppm). Ten negative male and 10 negative female control groups consisted of 184 animals. Rats were examinated twice daily, 7 days a week for toxicologic effects, weighted weekly during first month and then biweekly. Food consumption was determinated also. After 78 weeks of the study, five animals from each group in the higher dose were killed and necropsied and used for calculation of tumor incidence. At the end of the study were detected the following results: Low dose females had greater mortality than matched negative controls had, but at least 22 animals of each treated group survived to 78 weeks. In the low-dose group, 19 female rats and in high-dose group 16 female rats had mammary tumor. In the matched control group, male survivals were only 9 and females survivals was 10. In the high dose group, two females had mammary adenocarcinomas. Ten negative control groups, females, four of 184 animals had mammary carcinonoms. In the 184 control animals, the incidence of mammary tumors was 45%, which is less than the rate in either the low or high-dose groups but considerably above the 30 and 35% found in the matched and pooled negative controls respectively. One negative control group had an incidence exceeding the 73% in the low-dose group, and 2 other groups had incidences approaching the 62% in the high-dose groups.Finally, it has to be taken into account, that the results of the carcinogenicity of Thiosemicarbazide are ambigious.
Reference
Body weight of control groups: MALES: 51 wk 709 g (range of mean body wt 644-760 g); at 77 wk - 766 g (718-854 g); and at 104 wk - 737 g (635-812 g).
FEMALES, corresponding: 402 g (357-447), 486 g (441-549), and 541 g (487-629)
SURVIVALS at 52 wk : 100% for males and females.
Justification for classification or non-classification
According the available data Thiosemicarbazide it can not be classified as carcinogenic according to CLP Regulation no. 1272/2008 due to the ambiguous results.
Additional information
Key study: In the present publication from the Journal of the National Cancer Institute,the test item was tested for the carcinogenicity in the Charles River rats. In this chronic study chemicals was given to groups of 26 male and 26 female in the maximum tolerated doses and its half amount (75 ppm and 37.5 ppm) in a diet form during 78 weeks. After that, there was 6 months observation. Control groups (matched and pooled) were used in the study.Two positive control groups with the N-2 -fluorenylacetamide and ten negative male and 10 negative female control groups were used too. After 78 weeks of the study, five animals from each group in the higher dose were killed and necropsied and used for calculation of tumor incidence. At the end of the study were detected the following results: In the low-dose group, 19 female rats and in high-dose group 16 female rats had mammary tumor. The survivors numbered only 9 in the male group and 10 in the female group. In the high dose group, two females had mammary adenocarcinomas. Ten negative control groups, females, four of 184 animals had mammary carcinonoms. In the 184 control animals, the incidence of mammary tumors was 45%, which is less than the rate in either the low or high-dose groups but considerably above the 30 and 35% found in the matched and pooled negative controls respectively. One negative control group had an incidence exceeding the 73% in the low-dose group, and 2 other groups had incidences approaching the 62% in the high-dose groups. It has to be taken into account, that the results of the carcinogenicity of Thiosemicarbazide are ambigious.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
